Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - EYENOVIA, INC.tm2117268d1_ex99-1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 25, 2021

 

EYENOVIA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38365   47-1178401

(State or other jurisdiction of

incorporation)

(Commission File

Number)

(IRS Employer

Identification No.)

  

295 Madison Avenue, Suite 2400

New York, NY

(Address of principal executive offices)

 

10017

(Zip Code)

  

(917) 289-1117 

Registrant’s telephone number, including area code

 

Not applicable 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which

registered

Common Stock   EYEN   Nasdaq Capital Market

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

 

Item 8.01Other Events.

 

On May 25, 2021, the Company issued a press release announcing positive topline results from its VISION-1 Phase 3 clinical study of its proprietary pilocarpine formulation, MicroLine, for the treatment of presbyopia. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d)       Exhibits

 

Exhibit

Number

  Description
     
99.1   Press Release of the Company, dated May 25, 2021.
     

 

 

 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  EYENOVIA, INC.  
     
     
Date.  May 25, 2021 /s/ John Gandolfo  
  John Gandolfo  
  Chief Financial Officer  

 

 

 3